论文部分内容阅读
目的探讨支气管哮喘患者在吸入布地奈德福莫特罗干粉吸入剂治疗前后,其诱导痰中嗜酸细胞趋化因子(Eotaxin)及IL-17含量发生变化的临床意义。方法采用酶联免疫吸附法检测36例支气管哮喘患者(包括28例缓解期气管哮喘患者)吸入布地奈德福莫特罗干粉进行治疗前后诱导痰中嗜酸细胞趋化因子及IL-17产生的变化,并与30例健康对照组受试者的相关情况进行比较。结果支气管哮喘患者在病情急性发作期间布地奈德福莫特罗干粉后,诱导痰内嗜酸细胞趋化因子的含量明显高于缓解期的此病患者和健康对照组的受试者(P<0.05),急性发作期此病患者诱导痰中IL-17的含量明显高于健康对照组受试者(P<0.001)。结论吸入布地奈德福莫特罗可显著降低支气管哮喘患者病情急性发作期间体内嗜酸细胞趋化因子的含量,可减少气道分泌物中嗜酸粒细胞的含量。IL-17参与了支气管哮喘的气道炎症反应过程。
Objective To investigate the clinical significance of the changes of eotaxin and IL-17 in sputum induced by inhaled budesonide formoterol dry powder inhalation in patients with bronchial asthma. Methods The eosinophil chemotactic factor and IL-17 production in sputum were detected by enzyme-linked immunosorbent assay (ELISA) in 36 patients with bronchial asthma (including 28 patients with remission of tracheal asthma) inhaled budesonide formoterol powder Changes were compared with those in 30 healthy controls. Results The levels of eotaxin in induced sputum in patients with bronchial asthma were significantly higher than those in patients with remission and those in healthy controls during the acute episode (P < 0.05). The level of IL-17 in induced sputum of patients with acute exacerbation was significantly higher than that of healthy controls (P <0.001). Conclusion Inhaled budesonide formoterol can significantly reduce eosinophil chemokines levels in patients with bronchial asthma during the acute episode and reduce eosinophil levels in airway secretions. IL-17 is involved in the airway inflammatory response in bronchial asthma.